Despite its beneficial effect, ureteral stents may produce symptoms (such as hematuria, dysuria, frequency, urgency, urge incontinence and suprapubic or flank pain) that affect the quality of life in 70-80%. This study will be conducted to evaluate the role of Phosphodiestrase 5 inhibitor (Sildenafil Citrate) in relieving these symptoms.
Adult patient (\>18 years) who will undergo ureteral stent fixation after endoscopic procedures will be randomized between the study arms. Exclusion criteria: 1. Patients who had lower urinary tract symptoms before stent fixation. 2. Ureteral stent fixation after open surgery. 3. Known contraindications to Sildenafil Citrate
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
94
Urology and Nephrology Center, Mansoura University
Al Mansurah, Egypt
Ureteral Stent Symptoms Questionnaire (USSQ) Score
Comparison of total USSQ scores between study arms.
Time frame: 2-4 weeks
Number of participants with treatment-related adverse events
Analyzing frequency and severity of side effects of Sildenafil
Time frame: 2-4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.